At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 152 enrolled
Drug / intervention
JTE-451 Tablets +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of JTE-451 Administered for 16 Weeks in Subjects With Moderate to Severe Plaque Psoriasis (IMPACT-PS)
In Brief
A Phase 2 clinical trial evaluating JTE-451 Tablets and Placebo Tablets for Plaque Psoriasis and 2 related conditions. Completed, enrolled 152 participants across 33 sites in 3 countries.
Detailed Summary
Study to evaluate the efficacy and safety of JTE-451 administered for 16 weeks in subjects with moderate to severe plaque psoriasis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPlaque Psoriasis, Psoriasis, Skin Diseases
CountriesCanada, Poland, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20192020202120222023202420252026
Enrollment StartJan 2019
First PostedFeb 2019
Primary CompletionMar 2020
TodayJul 2026
First PostedFeb 6, 2019
Enrollment StartJan 17, 2019
Primary CompletionMar 13, 2020
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 7.4 years ago
Interventions
JTE-451 Tabletsdrug
Active drug tablets containing JTE-451
Placebo Tabletsdrug
Placebo tablets matching in appearance to the active drug tablets